The role of L-3-1-123-iodine-α-methyl tyrosine-SPECT in cerebral gliomas

M. Weckesser; D. Schmidt; P. Matheja; H. H. Coenen; K.-J. Langen

doi:10.1055/s-0038-1632273

Nuklearmedizin - NuclearMedicine, Inhaltsverzeichnis

Nuklearmedizin 2000; 39(08): 233-240
DOI: 10.1055/s-0038-1632273

Original Article

Schattauer GmbH

The role of L-3-1-123-iodine-α-methyl tyrosine-SPECT in cerebral gliomas

Die Bedeutung der L-3-I-123-lod-α-Methyl-Tyrosin-SPECT bei zerebralen Gliomen

M. Weckesser

¹Klinik und Poliklinik für Nuklearmedizin, Universität Münster (Direktor: Univ.-Prof. Dr. Dr. O. Schober)

,

D. Schmidt

⁴Nuklearmedizinische Klinik der Heinrich Heine-Universität Düsseldorf (Direktor: Univ.-Prof. Dr. H. W. Müller-Gärtner), Deutschland

,

P. Matheja

¹Klinik und Poliklinik für Nuklearmedizin, Universität Münster (Direktor: Univ.-Prof. Dr. Dr. O. Schober)

,

H. H. Coenen

³und Institut für Nuklearchemie (Direktor: Univ.-Prof. Dr. H. H. Coenen), Forschungszentrum Jülich

,

K.-J. Langen

²Institut für Medizin (Direktor: Univ.-Prof. Dr. K. Zilles)

› Institutsangaben

Abstract

Summary

L-3-1-123-iodine-a-methyltyrosine (IMT) is a 1-123-labelled amino acid which has been used for single photon emission computed tomography (SPECT) of cerebral gliomas for more than a decade. IMT-SPECT is able to detect tumor infiltration independent of disruptions of the blood-brain barrier which is often difficult with computed tomography or magnetic resonance tomography. The method is useful to detect tumor recurrences and helps to distinguish gliomas from non-neoplastic brain masses. IMT-SPECT is thus a valuable tool in the diagnostic evaluation and in therapy planning of patients with cerebral gliomas.

Zusammenfassung

L-3-1-123-lod-a-Methyl-Tyrosin (IMT) ist eine 1-123-markierte Aminosäure, die seit über 10 Jahren für die Diagnostik zerebraler Gliome mit der Einzei-Photonen-Emissions-Computertomographie (SPECT) eingesetzt wird. Die IMT-SPECT kann unabhängig von Störungen der Blut-Hirn-Schranke infiltrativ wachsende Tumoranteile darstellen, die in vielen Fällen computer-oder kernspintomographisch nicht differenziert werden können. Sie ist hilfreich bei der Erkennung von Gliomrezidiven und bei der Unterscheidung hirneigener Tumoren von nichtneoplastischen Läsionen. Die IMTSPECT trägt damit als ergänzende Untersuchung zu einer differenzierten Diagnostik und Therapieplanung bei Patienten mit zerebralen Gliomen bei.

Keywords

Brain tumor - glioma - scintigraphy - amino acid - SPECT

Schlüsselwörter

Hirntumor - Gliom - Szintigraphie - Aminosäure - SPECT

Volltext

Referenzen

Literatur
1 Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994; 34: 45-60.
2 Bader JB, Samnick S, Moringlane JR, Feiden W, Schaefer A, Kremp S, Kirsch CM. Evaluation of L-3-[1231]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: A comparative study with stereotactic biopsy. Eur J Nucl Med 1999; 26: 144-51.
3 Barker 2^nd FG, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant gliomas. Cancer 1997; 79: 115-26.
4 Bartenstein P, Grünwald F, Kuwert T, Tatsch K, Sabri O, Benkert O, Fahlbusch R, Gründer G, Herzholz K, Weiller C. Klinische Anwendungen der Single-Photonen-Emissionstomographie in der Neuromedizin. Teil 1 : Neuroonkologie. Epilepsien. Basalganglienerkrankungen. zerebrovaskuläre Erkrankungen. Nuklearmedizin. (im Druck).
5 Biersack HJ, Coenen HH, Stöcklin G, Reichmann K, Bockisch A, Oehr P, Kashab M, Rollmann O. Imaging of brain tumors with L-3-[¹²³I]Iodo-α-methyl tyrosine and SPECT. J Nucl Med 1989; 30: 110-2.
6 De Witte O, Levivier M, Violon P, Salmon I, Damhaut P, Wikler D, Hildebrand J, Brotchi J, Goldman S. Prognostic value positron emission tomography with (18F(fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996; 39: 470-6.
7 Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, Syrota A. [11C]L-methionine uptake in gliomas. Neurosurgery 1989; 25: 720-8.
8 Dethy S, Goldman S, Blecic S, Luxen A, Levivier M, Hildebrand J. Carbon-ll-methionine and fluorine-18-FDG PET study in brain hematoma. J Nucl Med 1994; 35: 1162-6.
9 Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, Dethy S, Brotchi J, Hildebrand J. Regional methionine and glucose uptake in high-grade gliomas: A comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997; 38: 1459-62.
10 Grosu AL, Weber W, Feldmann HJ, Wuttke B, Bartenstein P, Gross W, Lumenta C, Schwaiger M, Molls M. First Experience with I-123-alphamethyl-tyrosine SPECT in the 3-D radiation treatment planning of brain gliomas. Int J Radial Oncol Biol Phys 2000; 47: 517-26.
11 Guth-Tougelidis B, Muller S, Mehdorn MM, Knust EJ, Dutschka K, Reiners C. Anreicherung von DL-3-¹²³I-α-Methyl-Tyrosin in Hirntumor-Rezidiven. Nuklearmedizin 1995; 34: 71-5.
12 Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus RI, Mendoza G, Weber-Luxemburger G, Löttgen J, Thiel A, Wienhard K, Heiss WD. ‘C-methionine PET for differential diagnosis of low-grade-gliomas. Neurology 1998; 50: 1316-22.
13 Herholz K, Pietrzyk U, Voges J, Schroder R, Halber M, Treuer H, Sturm V, Heiss WD. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993; 79: 853-8.
14 Ishii K, Ogawa T, Hatazawa J, Kanno I, Inugami A, Fujita H, Shimosegawa E, Murakami M, Okudera T, Uemura K. High L-methvl-[llCjmethionine uptake in brain abscess: A PET study. J Comput Assist Tomogr 1993; 17: 660-1.
15 Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, Senda M. Re-evaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor tissues be measured in vivo?. J Nucl Med 1993; 34: 1936-43.
16 Jacobs A. Amino acid uptake in ischemically compromised brain tissue. Stroke 1995; 26: 1859-66.
17 Jager PL, Franssen EJ, Kool W, Szabo BG, Hoekstra HJ, Groen HJ, de Vries EG, van Imhoff GW, Vaalburg W, Piers DA. Feasibility of tumor imaging using L-3-[iodine-123]-iodoalpha-methyl-tyrosine in extracranial tumors. J Nucl Med 1998; 39: 1736-43.
18 Kallen K, Heiling M, Andersson AM, Brun A, Holtas S, Ryding E. Preoperative grading of glioma malignancy with thallium-201 singlephoton emission CT: Comparison with conventional CT. AJNR Am J Neuroradiol 1996; 17: 925-32.
19 Kawai K, Fujibayashi Y, Saji H, Yonekura Y, Konishi J, Kubodera A, Yokoyama A. a strategy for the study of cerebral amino acid transport using iodine-123-labeled amino acid radiopharmaceutical: 3-iodo-alpha-methyl-L-tyrosine. J Nucl Med 1991; 32: 819-24.
20 Kloss G, Leven M. Accumulation of radioiodinated tyrosine derivatives in the adrenal medulla and in melanomas. Eur J Nucl Med 1979; 4: 179-86.
21 Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R, Tamahashi N. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995; 36: 484-92.
22 Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, Samnick S, Maasjosthusmann U, Lerch H, Gildehaus FJ, Wassmann H, Schober O. Uptake of iodine-123-alphamethyltyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996; 23: 1345-53.
23 Kuwert T, Probst-Cousin S, Woesler B, Morgenroth C, Lerch H, Matheja P, Palkovic S, Schäfers M, Wassmann H, Gullotta F, Schober O. Iodine-123-alpha-methyl tyrosine in gliomas: Correlation with cellular density and proliferative activity. J Nucl Med 1997; 38: 1551-5.
24 Kuwert T, Woesler B, Morgenroth C, Lerch H, Schäfers M, Palkovic S, Matheja P, Brandau W, Wassmann H, Schober O. Diagnosis of recurrent glioma with SPECT and iodine-123-alphamethyl tyrosine. J Nucl Med 1998; 39: 23-7.
25 Langen KJ, Coenen HH, Roosen N, Kling P, Muzik O, Herzog H, Kuwert T, Stöcklin G, Feinendegen LE. SPECT studies of brain tumors with L-3-[¹²³I]Iodo-α-methyl tyrosine: Comparison with PET.^I124IMT and first clinical results. J Nucl Med 1990; 31: 281-6.
26 Langen KJ, Roosen N, Coenen HH, Kuikka JT, Kuwert T, Herzog H, Stöcklin G, Feinendegen LE. Brain and brain tumour uptake of L-3-[¹²³I]iodo-α-methyltyrosine: Competition with natural L-amino acids. J Nucl Med 1991; 32: 1225-8.
27 Langen KJ, Ziemons K, Kiwit JCW, Herzog H, Kuwert T, Bock WJ, Stöcklin G, Feinendegen LE, Müller-Gärtner HW. [¹²³I]-Iodo-a-methyltyrosine SPECT and [¹¹C]-L-methionine uptake in cerebral gliomas: A comparative study using SPECT and PET. J Nucl Med 1997; 38: 517-22.
28 Langen KJ, Xlauss RP, Holschbach M, Mühlensiepen H, Kiwit J.C.W, Zilles K, Coenen H.H, Müller-Gärtner H.W. Comparison of iodotyrosines and methionine uptake in a rat glioma model. J Nucl Med 1998; 39: 1596-9.
29 Langen KJ, Mühlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH. Transport mechanisms of 3-[¹²³I]iodo-a-methyl-L-tyrosine in a human glioma cell line: Comparison with [methyl-³H]-L-methionine. J Nucl Med 2000; 41: 1250-5.
30 Leeds NE, Jackson EF. Current imaging techniques for the evaluation of brain neoplasms. CurrOpin Oncol 1994; May: 6 (03) 254-61.
31 Matheja P, Rickert CH, Weckesser M, Palkovic S, Löttgen J, Riemann B, Kopka K, Kuwert T, Wassmann H, Paulus W, Schober O. Sequential scintigraphic strategy for the differentiation of brainlumours. Eur J Nucl Med 2000; 27: 550-8.
32 Mosskin M, von Holst H, Bergstrom M, Collins VP, Eriksson L, Johnstrom P, Noren G. Positron emission tomography with ‘C-methionine and computed tomography of intracranial tumours compared with histopathologic examination of multiple biopsies. Acta Radiol 1987; 28 (06) 673-81.
33 Mosskin M, Ericson K, Hindmarsh T, von Hoist H, Collins VP, Bergstrom M, Eriksson L, Johnstrom P. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 1989; 30: 225-32.
34 Ogawa T, Hatazawa J, Inugami A, Murakami M, Fujita H, Shimosegawa E, Noguchi K, Okudera T, Kanno I, Uemura K. Carbon-ll-methionine PET evaluation of intracerebral hematoma: Distinguishing neoplastic from non-neoplastic hematoma. J Nucl Med 1995; 36: 2175-9.
35 Riemann B, Stögbauer F, Kopka K, Halfter H, Lasic M, Schirmacher A, Kuwert T, Weckesser M, Ringelstein EB, Schober O. Kinetics of 3-[( 123)I]iodo-l-alpha-methyltyrosine transport in rat C6 glioma cells. Eur J Nucl Med 1999; 26: 1274-78.
36 Rollins NK, Lowry PA, Shapiro KN. Comparison of gadolinium-enhanced M R and thallium-201 single photon emission computed tomography in pediatric brain tumors. Pediatr Neurosurg 1995; 22: 8-14.
37 Schmidt D, Langen KJ, Herzog H, Wirths J, Holschbach M, Kiwit JC, Ziemons K, Coenen HH, Müller-Gärtner H. Whole body kinetics and dosimetry of L-3-[¹²³I]iodo-alpha-methyltyrosine. Eur J Nucl Med 1997; 24: 1162-6.
38 Schmidt D, Wunderlich G, Langen KJ, Ziemons K, Kiwit JCW, Holschbach M, Müller-Gärtner HW. I-123-a-Methyl-Tyrosine (IMT) SPECT for evaluation of chemotherapy in cerebral gliomas. J Nucl Med 1996; 37: 354P.
39 Tashima T, Morioka T, Nishio S, Hachisuga S, Fukui M, Sasaki M. Delayed cerebral radionecrosis with a high uptake of 11Cmethionine on positron emission tomography and ²⁰¹Tl-chloride on single-photon emission computed tomography. Neuroradiology 1998; 40: 435-8.
40 Tovi M, Lilja A, Bergstrom M, Ericsson A, Bergstrom K, Hartman M. Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol 1990; 31: 417-29.
41 Weber W, Bartenstein P, Gross MW, Kinzel D, Daschner H, Feldmann HJ, Reidel G, Ziegler SI, Lumenta C, Molls M, Schwaiger M. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997; 38: 802-8.
42 Weckesser M, Matheja P, Rickert CH, Löttgen J, Palkovic S, Riemann B, Paulus W, Wassmann H, Schober O. Evaluation of the extension of cerebral gliomas by scintigraphy. Strahlenther Onkol 2000; 176: 180-5.
43 Weckesser M, Matheja P, Rickert CH, Straeter R, Palkovic S, Riemann B, Kuriemann G, Schober O. Szintigraphische Malignitätskriterien werden durch pilozytische Astrozytome regelmäßig erfüllt. Nuklearmedizin 2000; 39: A73.
44 Wienhard K, Herholz K, Coenen HH, Rudolf J, Kling P, Stöcklin G, Heiss WD. Increased amino acid transport into brain tumors measured by PET of L-[2-18F]fluoro-tyrosine. J Nucl Med 1991; 32: 1338-46.
45 Woesler B, Kuwert T, Morgenroth C, Matheja P, Palkovic S, Schafers M, Vollet B, Schafers K, Lerch H, Brandau W, Samnick S, Wassmann H, Schober O. Non-invasive grading of primary brain tumours: results of a comparative study between SPET with ¹²³I-alpha-methyl tyrosine and PET with ¹⁸F-deoxyglucose. Eur J Nucl Med 1997; 24: 428-34.
46 Würker M, Herholz K, Voges J, Pietrzyk U, Treuer H, Bauer B, Sturm V, Heiss WD. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996; 23: 583-6.